Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Tumor inherent interferon regulators as biomarkers of long-term chemotherapeutic response in TNBC.

Brockwell NK, Rautela J, Owen KL, Gearing LJ, Deb S, Harvey K, Spurling A, Zanker D, Chan CL, Cumming HE, Deng N, Zakhour JM, Duivenvoorden HM, Robinson T, Harris M, White M, Fox J, Ooi C, Kumar B, Thomson J, Potasz N, Swarbrick A, Hertzog PJ, Molloy TJ, Toole SO, Ganju V, Parker BS.

NPJ Precis Oncol. 2019 Aug 29;3:21. doi: 10.1038/s41698-019-0093-2. eCollection 2019.

2.

Tumor inherent interferons: Impact on immune reactivity and immunotherapy.

Brockwell NK, Parker BS.

Cytokine. 2019 Jun;118:42-47. doi: 10.1016/j.cyto.2018.04.006. Epub 2018 Apr 19. Review.

PMID:
29681426
3.

Myoepithelial cell-specific expression of stefin A as a suppressor of early breast cancer invasion.

Duivenvoorden HM, Rautela J, Edgington-Mitchell LE, Spurling A, Greening DW, Nowell CJ, Molloy TJ, Robbins E, Brockwell NK, Lee CS, Chen M, Holliday A, Selinger CI, Hu M, Britt KL, Stroud DA, Bogyo M, Möller A, Polyak K, Sloane BF, O'Toole SA, Parker BS.

J Pathol. 2017 Dec;243(4):496-509. doi: 10.1002/path.4990. Epub 2017 Oct 31.

PMID:
29086922
4.

Neoadjuvant Interferons: Critical for Effective PD-1-Based Immunotherapy in TNBC.

Brockwell NK, Owen KL, Zanker D, Spurling A, Rautela J, Duivenvoorden HM, Baschuk N, Caramia F, Loi S, Darcy PK, Lim E, Parker BS.

Cancer Immunol Res. 2017 Oct;5(10):871-884. doi: 10.1158/2326-6066.CIR-17-0150. Epub 2017 Aug 28.

Supplemental Content

Loading ...
Support Center